For Research Use Only. Not for Human or Veterinary Use.
Overview
Humanin is a 24-amino-acid mitochondrial-derived peptide (MDP), first identified in 2001 for its neuroprotective activity and encoded within the mitochondrial 16S ribosomal RNA gene. It has since been characterised in preclinical research as a broad-spectrum cytoprotective peptide — studied against amyloid-β toxicity, apoptosis, oxidative stress, insulin resistance and age-related decline. It is a research compound.
Humanin is studied as a cytoprotective peptide that blocks the intrinsic (mitochondrial) apoptosis pathway, principally by binding pro-apoptotic Bax and Bid so they cannot permeabilise the mitochondrial outer membrane. It also engages survival-signalling and stress-response pathways, which underpins its broad protective profile.
Component
Detail
Primary targets
Bax, Bid, IGFBP3
Bax / Bid inhibition
Blocks mitochondrial outer-membrane permeabilization and caspase activation
IGFBP3 binding
Modulates IGF-1 signalling
STAT3 activation
Via gp130 receptor engagement
Akt pathway
PI3K/Akt survival signalling
Anti-oxidative
Studied for raising SOD2 and catalase
System
Studied effect
Central nervous system
Neuroprotection against amyloid-β toxicity
Cardiovascular
Protection against ischemia–reperfusion
Metabolic
Improved insulin sensitivity (IGFBP3 modulation)
Longevity
Extended lifespan in model organisms
💊Pharmacology
Parameter
Value
Half-life (t½)
≈ 1–3 h (plasma, estimated)
Bioavailability (SC)
≈ 40–60% (estimated)
Bioavailability (oral)
Poor (proteolytic degradation)
Protein binding
Moderate (IGFBP3 and albumin)
Metabolism
Proteolytic degradation
Route of administration
SC, IV, IP (research)
Elimination
Renal (peptide fragments)
📚Research Evidence
Humanin has a large preclinical literature across neuroprotection, metabolism and aging. Representative models and their focus are named below; specific numerical outcomes are not restated here as claims.
Model
Research focus
Reference
Primary neuronal culture
Protection against amyloid-β toxicity
Hashimoto Y, et al. (2001)
Alzheimer’s mouse model
Amyloid burden and behaviour
Humanin preclinical literature
Type-2-diabetes mouse model
Insulin sensitivity and glucose
Muzumdar RH, et al.
Model-organism aging
Lifespan and healthspan
Humanin preclinical literature
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
Reported direction / finding
Context
Reference
Protection against amyloid-β toxicity
primary neurons
Hashimoto Y et al., 2001
Improved insulin sensitivity
diabetic mice
Muzumdar RH et al.
Cytoprotection via Bax/Bid inhibition
apoptosis models
Humanin literature
For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.
⚗️Dosing & Reconstitution Reference
Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.
Parameter
Reference value
Research dose range (literature)
≈ 2–8 mg per injection in study protocols
Reconstitution solvent
Bacteriostatic water (0.9% benzyl alcohol)
Final concentration
≈ 5–10 mg/mL
Storage (lyophilized)
−20°C, protected from light
Storage (reconstituted)
2–8°C, up to ~7 days
Do not use
If the solution is cloudy or contains particulates
🛡️Safety Profile
Published research observations, provided for reference only. This material is not for human or veterinary use.
Category
Published observations
Local tolerability
Mild injection-site reactions
Cytotoxicity
No cytotoxicity observed in cell assays
Genotoxicity
Negative in standard assays
General
Well tolerated in reported animal studies
Status
For research use only; not for human or veterinary application
📐Physicochemical Properties
Property
Value
Physical state
White to off-white lyophilized powder
Solubility (water)
Freely soluble (> 50 mg/mL)
logP (octanol/water)
≈ −2.5 (hydrophilic)
Notable residues
Contains one methionine and one cysteine
pH (reconstituted)
5.0–6.5
Stability (lyophilized)
≥ 24 months at −20°C
🏭Synthesis & Manufacturing
Humanin is a 24-residue peptide made by Fmoc solid-phase synthesis. Its four consecutive leucines and its single cysteine and methionine (both oxidation-sensitive) are the points that need careful handling and scavengers at cleavage.
Step
Detail
Strategy
Fmoc solid-phase peptide synthesis
Resin
Rink amide MBHA resin
Coupling
HBTU / HOBt with DIPEA
Sensitive residues
Cys and Met protected against oxidation; scavengers at cleavage
Cleavage
TFA / TIPS / H₂O with thiol scavengers
Purification
Preparative RP-HPLC (C18, TFA/ACN gradient)
Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
Critical quality attributes: correct molecular weight and low deletion-peptide content. Contains methionine and cysteine — protect from oxidation during handling.
🔎Analytical Methods
Method
Parameter
Typical result
RP-HPLC (C18, UV 214 nm)
Purity
≥ 98%
HPLC retention
C18, reversed-phase TFA/ACN gradient
Single main peak
ESI-MS (positive mode)
Identity / mass
consistent with the 24-residue peptide
MALDI-TOF
Mass confirmation
consistent with the 24-residue peptide
Amino-acid analysis
Composition
Consistent with the stated sequence
LC-MS (extracted ion)
Deletion-peptide impurities
Within specification
Karl Fischer
Water content
< 6%
LAL assay
Endotoxin
Within specification
Ion chromatography
Residual TFA
< 500 ppm
Representative RP-HPLC purity method:
Column: C18, 5 µm, 250 × 4.6 mm
Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
Confirmatory LC-MS: ESI positive mode (consistent with the 24-residue peptide). Contains methionine and cysteine — protect from oxidation during handling.
📈Stability Data
Representative stability behaviour under common storage, handling and formulation conditions.
Condition
Duration
Result
Lyophilized, −20°C, dark
≥ 24 months
No significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark
≥ 12 months
Minimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)
3 months
< 5% degradation
Reconstituted, 2–8°C, dark
7–14 days
Minor degradation
Reconstituted, 25°C
24–48 h
Use promptly
Light exposure (ICH Q1B)
1.2 M lux·h
Generally light-stable
Freeze–thaw (−20°C ⇄ 25°C)
3 cycles
Acceptable — aliquot to avoid repeats
Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
Minimise freeze-thaw cycles; aliquot material used across many sessions.
Key factor: Contains methionine and cysteine — protect from oxidation during handling.
📖Selected References
Hashimoto Y, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Aβ. Proceedings of the National Academy of Sciences, 2001.
Muzumdar RH, et al. Humanin: a novel central regulator of peripheral insulin action (metabolic research literature).
Yen K, Lee C, Mehta H, Cohen P. The emerging role of the mitochondrial-derived peptide humanin in stress, metabolism and disease (review literature).
✅Quality & Supply
HPLC ≥ 98% purity with a Certificate of Analysis per batch
Identity confirmed by LC-MS
Research samples through to bulk, with worldwide delivery